Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables (2019 - 2021)

Historic Receivables for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Q4 2022 value amounting to $700000.0.

  • 4D Molecular Therapeutics' Receivables fell 629.18% to $700000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $700000.0, marking a year-over-year decrease of 629.18%. This contributed to the annual value of $700000.0 for FY2022, which is 629.18% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Receivables of $700000.0 as of Q4 2022, which was down 629.18% from $747000.0 recorded in Q4 2021.
  • In the past 5 years, 4D Molecular Therapeutics' Receivables registered a high of $1.5 million during Q4 2020, and its lowest value of $561000.0 during Q1 2021.
  • Its 4-year average for Receivables is $902000.0, with a median of $769000.0 in 2021.
  • In the last 5 years, 4D Molecular Therapeutics' Receivables surged by 3185.45% in 2020 and then tumbled by 4973.08% in 2021.
  • Over the past 4 years, 4D Molecular Therapeutics' Receivables (Quarter) stood at $1.1 million in 2019, then skyrocketed by 31.85% to $1.5 million in 2020, then plummeted by 49.73% to $747000.0 in 2021, then decreased by 6.29% to $700000.0 in 2022.
  • Its last three reported values are $700000.0 in Q4 2022, $747000.0 for Q4 2021, and $791000.0 during Q3 2021.